Targeting neurotensin as a potential novel approach for the treatment of autism by Ahmad Ghanizadeh
COMMENTARY Open Access
Targeting neurotensin as a potential novel
approach for the treatment of autism
Ahmad Ghanizadeh1,2
Abstract
The pathophysiology of autism remains obscure. Recently, serum neurotensin levels in children with autistic disor-
der have been found to be higher than those of normal children. Neurotensin is known to intensify neuronal
NMDA-mediated glutamate signaling, which may cause apoptosis in autism. Further, an imbalance of glutamate/
GABAergic system in autism has been described. These observations lead to a postulate that neurotensin may
accentuate the hyperglutaminergic state in autism, leading to apoptosis. Targeting neurotensin might be a possible
novel approach for the treatment of autism.
A recently published study in Journal of Neuroinflam-
mation reports the finding that neurotensin (NT) is ele-
vated in the serum of young children with autistic
disorder [1]. In cultured rat cortical neurons, NT has
been shown to increase glutamate outflow and to inten-
sify N-methyl D-aspartic acid- (NMDA-) mediated
glutamate signaling [2]. In addition, NT may enhance
glutamate transmission and, in particular, activate
NMDA receptors [3,4]. Such overstimulation of NMDA
glutamate receptors can lead to excitotoxicity [5]. Thus,
factors that modulate glutamatergic transmission may
affect glutamate-induced cell apoptosis.
Previous studies have suggested a possible role for a
hyperglutaminergic state in autism [6]. Further, an
antagonist of the NMDA glutamate receptor, meman-
tine, has been shown to improve some symptoms in
autism [7]. In contrast, there have been conflicting
reports regarding the effects of NT on GABAergic
synapses. At least one study has reported that NT inhi-
bits GABAergic synaptic transmission in rats [8]. Other
studies have indicated that NT enhances GABA release
[9], activates GABAergic interneurons in rat prefrontal
cortex [10], and increases GABAergic activity in rat hip-
pocampus [11]. NT may act in the CNS as an atypical
neuroleptic [12]. Studies using an antagonist of the NT
receptor subtype 1 (NTS1) have elucidated the functions
driven by this receptor [13], and antagonism of NTS1
has been suggested as a novel therapeutic approach for
the treatment of Parkinson’s disease [4].
The higher serum levels of NT in young patients with
autistic disorder does not necessarily indicate a casual
role in autism [1]. Elevated NT levels in autistic disorder
could be a result of inflammation. However, considering
the known imbalance in glutamate-to-GABA ratios in
children with autism [14], the higher levels of glutamate
in autism [14], the downregulation of GABA(A) recep-
tors in autism [15], and the role of NT in excessive acti-
vation of the NMDA receptor and apoptosis [3,4], NT
may mediate brain damage in addition to activating
inflammatory processes in autism. These observations
collectively suggest a hypothesis that modulation of NT
or of its receptors, in combination with traditional
drugs, may provide a novel approach for the manage-
ment of autism.
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